How Oxtoby was paid
$2.6M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Andrew OxtobyPresident and Chief Executive Officer | $537,733 | — | $1,687,076 | $344,306 | — | $2,569,115 |
| Matthew FeinsodChief Medical Officer | $457,732 | — | $1,008,403 | $207,636 | — | $1,673,771 |
| Matthew GallFormer Chief Financial Officer | $80,833 | — | $949,279 | $34,495 | — | $1,064,607 |
| Vikas SinhaAlloVir’s Former Chief Executive Officer, President and Chief Financial Officer | $81,106 | — | — | — | $1,019,848 | $1,100,954 |
| Brett HagenChief Accounting Officer and AlloVir’s former Chief Accounting Officer | $397,301 | $67,814 | $295,417 | $121,512 | $557,130 | $1,439,174 |
What changed and why
- $2.6MAndrew Oxtoby received total compensation of $2,569,115 in fiscal 2025, an increase from $1,965,153 in the prior year.
- $655KBase salaries for executive officers were increased for fiscal 2026, with the CEO base salary set at $655,200.
- Annual non-equity incentive cash bonuses were awarded based on achievement of specified corporate goals.
- Aon plc served as the independent compensation consultant to the compensation committee during fiscal 2025.
- Certain former executives received severance and retention payments in connection with corporate transaction activities.
Other Kalaris Therapeutics proxy statements
- 2025 proxy statement
Vikas Sinha paid $544,400 (-81% on the year).
Filed Jul 01, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.